Reversible PulpitisNCT01622153
Electrical and Formocresol Pulpotomy in Primary Molars
A study testing Formocresol application after pulpotomy preparation and GENTLEray 980 Soft Tissue diode laser in people with Reversible Pulpitis and Caries, run by University Hospitals Cleveland Medical Center at 1 site in United States.
Trial summary
1. The investigator hypothesize that the Laser pulpotomy will provide adequate and comparable success clinically in primary molars. 2. The investigators hypothesize that the Laser pulpotomy will provide adequate and comparable success radiographically in primary molars. Read more about this study
- Who is it for?
- Ages 3 to 8 years
- Conditions the study is for
- Reversible Pulpitis, Caries
- What is being tested?
- Formocresol application after pulpotomy preparation and GENTLEray 980 Soft Tissue diode laser
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2011to Jun 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 8 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Restorable carious primary molars with reversible pulpitis and free of clinical or radiographic signs of pulp pathology
- Males and females
- Children ages 3-8 years old
- Children classified under ASA I or II status
Who cannot join
- Excluded will be primary molars with clinical or radiographic signs of pathology
- Children not within age range
- Absence of parent/caregiver
- Mentally disabled parent/caregiver
- Patients not returning for 6 month and 12 month follow up examination appointment
Trial locations and contacts
1 site in 1 country.
United States1 site
University Hospital-Rainbow Babies & Children's Hospital
Cleveland, Ohio, 44106
About this study
Official title: A Prospective Study and Clinical Evaluation of Pre & Post Operative Treatment Comparison of Electrical and Formocresol Pulpotomy Procedures in Primary Molars of Children Undergoing General Anesthesia
- The investigator hypothesize that the Laser pulpotomy will provide adequate and comparable success clinically in primary molars.
- The investigators hypothesize that the Laser pulpotomy will provide adequate and comparable success radiographically in primary molars.
Read the detailed description
The health of teeth, their supporting tissues and maintaining their integrity is the primary goal of pulp therapy. Conservative pulp therapy for primary teeth aims to maintain pulp vitality, reduce the need for a pulpectomy, and promote the integrity and retention of such teeth until appropriate exfoliation.(51) A pulpotomy is usually performed for carious exposures of primary teeth with normal pulp or reversible coronal pulpitis, or primary teeth pulpally exposed by trauma (AAPD 2009). A pulpotomy requires healthy radicular pulp capable of healing after amputation of inflamed or infected coronal pulp [Fuks and Eidelman, 1991]. After the coronal pulp is amputated, the remaining vital radicular pulp tissue surface is treated with a long-term clinically successful medicament such as Buckley's Solution of formocresol. (46-52) Electrosurgery has also demonstrated success. (53) The coronal pulp chamber is filled with zinc/oxide, eugenol, or other suitable base, and the tooth is restored with a restoration that seals the tooth from microleakage. The most effective long-term restoration has been shown to be a stainless steel crown.
When the coronal tissue is amputated, the remaining radicular tissue is judged to be vital without suppuration, purulence, necrosis, or excessive hemorrhage that cannot be controlled with a damp cotton pellet after several minutes. In addition to this, if there are no radiographic signs of infection or pathologic resorption then a pulpotomy procedure is indicated. (Camp JH, Fuks AB) Despite concerns of toxicity, mutagenicity and carcinogenicity [Swenberg et al., 1980; Goldmacher and Thilly, 1983; Ranly and Horn, 1987], formocresol (FC) remains a commonly used primary tooth pulpotomy medicament [Hingston et al., 2007]. Various clinical and radiographic success rates (59-100%) have been reported [Mejare, 1979; Naik and Hegde, 2005], attributed to intra-patient variations, clinician and assessor factors, FC concentrations and application times, coronal seal, and study durations.
As technology continues to improve, it allows dentists to treat patients with greater precision, meaning less pain and quicker healing. The diode laser is used in many different dental procedures. It is most commonly used to perform soft-tissue surgery in the mouth. The diode laser's high-energy beam kills bacteria, thus it is often used to sterilize areas of the mouth before or during root canal procedures. (Laser-dentistry/diode-laser) The diode laser represents a whole new way of thinking about dental care. Laser treatment is less painful, more convenient, and more effective than many traditional dental treatments. A study by Bahrololoomi Z, Moeintaghavi A, comparing FC and electrosurgery pulpotomy after nine months of follow up found that clinical and radiographical success rates were 96% and 84% respectively in the electrosurgical group and 100% and 96.8% respectively in the formocresol group. There was no statistical significance and the results showed that the failure rates for electrosurgery pulpotomy were equal to those of formocresol pulpotomy.
Purpose:
Dental care has recently been identified as the most prevalent unmet health need amongst US children (AAPD 2009). This research study investigates another treatment method to help provide dental care to these children by evaluating the success rate of a laser (electrical) pulpotomy compared to formocresol pulpotomy in primary molars with carious pulp exposure. There is a need to study and assess the laser pulpotomy method in order to help create a more efficient and painless treatment.
Study Design and Procedures:
We will perform a prospective study and clinical evaluation of patients ranging from ages 3-8 years old treated under general anesthesia from June, 2010 to June, 2014. The review and analysis will be completed over a four year time period. The patients participating in this study will include those presenting themselves as patients to the Tapper Pediatric Dentistry clinic at Rainbow Babies Children's Hospital. These patients will only be scheduled to be treated in the operating room when it is indicated as the best treatment option. Treatment under General Anesthesia is indicated when: 1. Patient is uncooperative due to a lack of psychological or emotional maturity and/or mental, physical, or medical disability. 2. Patients for whom local anesthesia is ineffective because of acute infection, anatomic variations, or allergy. 3. Extremely uncooperative, fearful, anxious, or uncommunicative child or adolescent. 4. Patients requiring significant surgical procedures. 5. Patients for whom the use of GA may protect the developing psyche and/or reduce medical risk. 6. Patients requiring immediate, comprehensive oral/dental care (AAPD 2009). The patients will then be consented and informed on the same day of the OR appointment. They will be given specific post-op instructions both verbally and in written form. They will be scheduled for a two-week follow-up appointment in the clinic following dental treatment. Informed consent must be obtained by the parent/guardian of the patients that will participate in the study and receive pulpotomy treatment with the laser technique. Other patients, regardless of the study, will have pulpotomy treatment using the traditional formocresol technique.
All patients will receive general endotracheal anesthesia while receiving comprehensive dental treatment. General anesthesia will be provided using a combination of inhaled anesthetics and propofol intravenously. General anesthesia will be supplemented with intravenous opioid analgesics, ketorolac unless contraindicated, and anti-mimetics. The anesthetic approach will not be influenced by participation or non-participation of patients in the study.
The patient's name, date of birth, and medical history will be obtained from each patient chart. This PHI will be utilized to keep track of patient demographics for the study. Patients scheduled for the operating room will be seen for a post-op two week follow up appointment and regular dental visits regardless of whether or not they are participating in the study.
Of the eligible subjects a randomized clinical trial will be performed on 90 primary molars in children aged 3-8 years. Two preoperative bite wing radiographs will be taken. The teeth will be treated for pulp therapy using either a conventional formocresol (30 controls and 30 study teeth) or GENTLEray 980 Soft Tissue diode laser (30 study teeth) technique. 30 Controls: The procedure for these 30 subjects is conducted using a #8 round diamond bur to remove occlusal tooth structure for pulp chamber access and removal of coronal pulp. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. After this, a Chlorhexidine Gluconate 0.12% rinse will be applied to decrease the bacterial level. Then, placement of 35% Phosphoric Acid Etch for 15-30 seconds is rinsed off and dried until the tooth has a white, chalky appearance. One layer of Optibond Solo is placed into the pulp chamber and light cured for 10 seconds with a 3M ESPE Elipar S10 light curing device. IRM (Zinc Oxide Eugenol) cement will then be placed to seal the pulp chamber. A stainless steel crown will be cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration. 30 Conventional Formocresol: The procedure for these 30 subjects is conducted using a #8 round diamond bur to remove occlusal tooth structure for pulp chamber access and removal of coronal pulp. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. After this, a Chlorhexidine Gluconate 0.12% rinse will be applied to decrease the bacterial level. Then, placement of 35% Phosphoric Acid Etch for 15-30 seconds is rinsed off and dried until the tooth has a white, chalky appearance. One layer of Optibond Solo is placed into the pulp chamber and light cured for 10 seconds with a 3M ESPE Elipar S10 light curing device. Dyract compomer will then be placed to seal the pulp chamber. A stainless steel crown is cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration. 30 Laser Diode: The procedure for these 30 subjects is conducted using a #8 round diamond bur to remove occlusal tooth structure for pulp chamber access and removal of coronal pulp. Then a GENTLEray 980 Soft Tissue diode laser (Power: 3.0W, Mode: PW, Fiber: 300µm, Ton: 100ms, Toff: 100ms, Timer: cont) will be used to vaporize the residual pulp tissue and complete hemostasis. After completion of hemostasis, a Chlorhexidine Gluconate 0.12% rinse will be applied to decrease the bacterial presence. Subjects will then receive placement of 35% Phosphoric Acid Etch for 15-30 seconds followed by 10 second light cured optibond solo. IRM (Zinc Oxide Eugenol) cement is then placed to seal the pulp chamber. A stainless steel crown cemented with Ketac Cement for the full coverage final restoration completes the pulpotomy procedure.
Following the pulpotomy procedures, the teeth will be evaluated for clinical and radiographic success at 6 months post-op and 12 months post-op appointments at the Tapper Pediatric Dental Clinic at Rainbow Babies Children's Hospital. The study teeth treated will be evaluated clinically based on the presence of the following: (1) pain (2) abscess (3) mobility. Radiographic success will be determined by evaluating a bite wing x-ray taken at the two post-op appointments for the presence of the following: (1) internal resorption (2) external resorption and (3) furcation radiolucency.
Risks:
The only physical risk in laser therapy is the risk of eye damage. While eye damage has not been reported to date, we must still consider it as a possible risk. Because these study subjects will be under General Anesthesia their eyes will already be closed and covered. Suitable protective goggles should be worn by the investigator and assistants. Other possible risks associated with this study include risks from anesthesia- (Nausea, vomiting, epistaxis, fever, discomfort/pain). There are minimal to no risks involved in this research study.
Benefits:
Pulpotomy treatment maintains the vitality of the tooth as well as the supporting tissues. The longevity and prognosis of having a laser pulpotomy versus a formocresol pulpotomy treatment has been considered to be just as beneficial. Through this research study, we can further prove this new finding. Maintaining your primary dentition is extremely important and this study will provide insight on how advances in dental technology can help better treat carious teeth in more efficient and painless ways.
Alternatives:
Due to the nature of this research the only alternative is to not participate in this study.
- Conditions
- Reversible Pulpitis, Caries
- Being tested
- Formocresol application after pulpotomy preparation, GENTLEray 980 Soft Tissue diode laser
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Formocresol application after pulpotomy preparationProcedure or surgery
Also called Buckley's solution, baby root canal, primary root canal
1:5 Buckley's Formocresol dilution applied for 5 minutes or until hemostasis achieved
GENTLEray 980 Soft Tissue diode laserProcedure or surgery
Also called soft tissue laser, electrosurgery, baby root canal
Application to pulp chamber until hemostasis achieved
| Study group | Role | What they receive |
|---|---|---|
| Formocresol (control) | Placebo comparator | This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. IRM (Zinc Oxide Eugenol) cement will then be placed to seal the pulp chamber. A stainless steel crown will be cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration. Receives: Procedure: Formocresol application after pulpotomy preparation |
| Laser | Active comparator | This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Then a GENTLEray 980 Soft Tissue diode laser (Power: 3.0W, Mode: PW, Fiber: 300µm, Ton: 100ms, Toff: 100ms, Timer: cont) will be used to vaporize the residual pulp tissue and complete hemostasis. IRM (Zinc Oxide Eugenol) cement is then placed to seal the pulp chamber. A stainless steel crown cemented with Ketac Cement for the full coverage final restoration completes the pulpotomy procedure. Receives: Procedure: GENTLEray 980 Soft Tissue diode laser |
What is being measured
The primary outcome is the main question the study is designed to answer.
Radiographic
Failure is identified as radiographic: furcation radiolucency, external root resorption
Measured: 6, 12, and 18 months
Secondary outcomes (1)
Clinical
Failure determined by clinical presence of: mobility, abscess, spontaneous pain, suppuration
Measured: 6, 12, 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2012 (estimated)
- Study startJun 2011
- Primary completionJun 2014
- Study completionJun 2014
Why it stopped: Use of Formocresol for pulpotomies ws discontinued.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Reversible PulpitisStudies of the same condition, open and under way.
- More trials run by University Hospitals Cleveland Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gerald Feretti, DDS, MS, MPH, University Hospitals Cleveland Medical Center
- Investigators
- Gerald A Ferretti, DDS, MS, MPH, Principal investigator, University Hospitals Cleveland Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01622153
- Sponsor's protocol ID
- 021117
- Status last verified
- May 2017
- First submitted
- 14 Jun 2012
- Last updated
- 10 May 2017
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Study and Clinical Evaluation of Pre & Post Operative Treatment Comparison of Electrical and Formocresol Pulpotomy Procedures in Primary Molars of Children Undergoing General Anesthesia
- ClinicalTrials.gov ID
- NCT01622153
- Acronym / sponsor ID
- 021117
- Conditions
- Reversible Pulpitis, Caries
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Use of Formocresol for pulpotomies ws discontinued.
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- University Hospitals Cleveland Medical CenterUniversity, hospital or other
- Study start
- Jun 2011
- Primary completion
- Jun 2014 (actual)
- Study completion
- Jun 2014 (actual)
- First posted
- 18 Jun 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- The investigator hypothesize that the Laser pulpotomy will provide adequate and comparable success clinically in primary molars.
- The investigators hypothesize that the Laser pulpotomy will provide adequate and comparable success radiographically in primary molars.
Detailed description
The health of teeth, their supporting tissues and maintaining their integrity is the primary goal of pulp therapy. Conservative pulp therapy for primary teeth aims to maintain pulp vitality, reduce the need for a pulpectomy, and promote the integrity and retention of such teeth until appropriate exfoliation.(51) A pulpotomy is usually performed for carious exposures of primary teeth with normal pulp or reversible coronal pulpitis, or primary teeth pulpally exposed by trauma (AAPD 2009). A pulpotomy requires healthy radicular pulp capable of healing after amputation of inflamed or infected coronal pulp [Fuks and Eidelman, 1991]. After the coronal pulp is amputated, the remaining vital radicular pulp tissue surface is treated with a long-term clinically successful medicament such as Buckley's Solution of formocresol. (46-52) Electrosurgery has also demonstrated success. (53) The coronal pulp chamber is filled with zinc/oxide, eugenol, or other suitable base, and the tooth is restored with a restoration that seals the tooth from microleakage. The most effective long-term restoration has been shown to be a stainless steel crown.
When the coronal tissue is amputated, the remaining radicular tissue is judged to be vital without suppuration, purulence, necrosis, or excessive hemorrhage that cannot be controlled with a damp cotton pellet after several minutes. In addition to this, if there are no radiographic signs of infection or pathologic resorption then a pulpotomy procedure is indicated. (Camp JH, Fuks AB) Despite concerns of toxicity, mutagenicity and carcinogenicity [Swenberg et al., 1980; Goldmacher and Thilly, 1983; Ranly and Horn, 1987], formocresol (FC) remains a commonly used primary tooth pulpotomy medicament [Hingston et al., 2007]. Various clinical and radiographic success rates (59-100%) have been reported [Mejare, 1979; Naik and Hegde, 2005], attributed to intra-patient variations, clinician and assessor factors, FC concentrations and application times, coronal seal, and study durations.
As technology continues to improve, it allows dentists to treat patients with greater precision, meaning less pain and quicker healing. The diode laser is used in many different dental procedures. It is most commonly used to perform soft-tissue surgery in the mouth. The diode laser's high-energy beam kills bacteria, thus it is often used to sterilize areas of the mouth before or during root canal procedures. (Laser-dentistry/diode-laser) The diode laser represents a whole new way of thinking about dental care. Laser treatment is less painful, more convenient, and more effective than many traditional dental treatments. A study by Bahrololoomi Z, Moeintaghavi A, comparing FC and electrosurgery pulpotomy after nine months of follow up found that clinical and radiographical success rates were 96% and 84% respectively in the electrosurgical group and 100% and 96.8% respectively in the formocresol group. There was no statistical significance and the results showed that the failure rates for electrosurgery pulpotomy were equal to those of formocresol pulpotomy.
Purpose:
Dental care has recently been identified as the most prevalent unmet health need amongst US children (AAPD 2009). This research study investigates another treatment method to help provide dental care to these children by evaluating the success rate of a laser (electrical) pulpotomy compared to formocresol pulpotomy in primary molars with carious pulp exposure. There is a need to study and assess the laser pulpotomy method in order to help create a more efficient and painless treatment.
Study Design and Procedures:
We will perform a prospective study and clinical evaluation of patients ranging from ages 3-8 years old treated under general anesthesia from June, 2010 to June, 2014. The review and analysis will be completed over a four year time period. The patients participating in this study will include those presenting themselves as patients to the Tapper Pediatric Dentistry clinic at Rainbow Babies Children's Hospital. These patients will only be scheduled to be treated in the operating room when it is indicated as the best treatment option. Treatment under General Anesthesia is indicated when: 1. Patient is uncooperative due to a lack of psychological or emotional maturity and/or mental, physical, or medical disability. 2. Patients for whom local anesthesia is ineffective because of acute infection, anatomic variations, or allergy. 3. Extremely uncooperative, fearful, anxious, or uncommunicative child or adolescent. 4. Patients requiring significant surgical procedures. 5. Patients for whom the use of GA may protect the developing psyche and/or reduce medical risk. 6. Patients requiring immediate, comprehensive oral/dental care (AAPD 2009). The patients will then be consented and informed on the same day of the OR appointment. They will be given specific post-op instructions both verbally and in written form. They will be scheduled for a two-week follow-up appointment in the clinic following dental treatment. Informed consent must be obtained by the parent/guardian of the patients that will participate in the study and receive pulpotomy treatment with the laser technique. Other patients, regardless of the study, will have pulpotomy treatment using the traditional formocresol technique.
All patients will receive general endotracheal anesthesia while receiving comprehensive dental treatment. General anesthesia will be provided using a combination of inhaled anesthetics and propofol intravenously. General anesthesia will be supplemented with intravenous opioid analgesics, ketorolac unless contraindicated, and anti-mimetics. The anesthetic approach will not be influenced by participation or non-participation of patients in the study.
The patient's name, date of birth, and medical history will be obtained from each patient chart. This PHI will be utilized to keep track of patient demographics for the study. Patients scheduled for the operating room will be seen for a post-op two week follow up appointment and regular dental visits regardless of whether or not they are participating in the study.
Of the eligible subjects a randomized clinical trial will be performed on 90 primary molars in children aged 3-8 years. Two preoperative bite wing radiographs will be taken. The teeth will be treated for pulp therapy using either a conventional formocresol (30 controls and 30 study teeth) or GENTLEray 980 Soft Tissue diode laser (30 study teeth) technique. 30 Controls: The procedure for these 30 subjects is conducted using a #8 round diamond bur to remove occlusal tooth structure for pulp chamber access and removal of coronal pulp. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. After this, a Chlorhexidine Gluconate 0.12% rinse will be applied to decrease the bacterial level. Then, placement of 35% Phosphoric Acid Etch for 15-30 seconds is rinsed off and dried until the tooth has a white, chalky appearance. One layer of Optibond Solo is placed into the pulp chamber and light cured for 10 seconds with a 3M ESPE Elipar S10 light curing device. IRM (Zinc Oxide Eugenol) cement will then be placed to seal the pulp chamber. A stainless steel crown will be cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration. 30 Conventional Formocresol: The procedure for these 30 subjects is conducted using a #8 round diamond bur to remove occlusal tooth structure for pulp chamber access and removal of coronal pulp. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. After this, a Chlorhexidine Gluconate 0.12% rinse will be applied to decrease the bacterial level. Then, placement of 35% Phosphoric Acid Etch for 15-30 seconds is rinsed off and dried until the tooth has a white, chalky appearance. One layer of Optibond Solo is placed into the pulp chamber and light cured for 10 seconds with a 3M ESPE Elipar S10 light curing device. Dyract compomer will then be placed to seal the pulp chamber. A stainless steel crown is cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration. 30 Laser Diode: The procedure for these 30 subjects is conducted using a #8 round diamond bur to remove occlusal tooth structure for pulp chamber access and removal of coronal pulp. Then a GENTLEray 980 Soft Tissue diode laser (Power: 3.0W, Mode: PW, Fiber: 300µm, Ton: 100ms, Toff: 100ms, Timer: cont) will be used to vaporize the residual pulp tissue and complete hemostasis. After completion of hemostasis, a Chlorhexidine Gluconate 0.12% rinse will be applied to decrease the bacterial presence. Subjects will then receive placement of 35% Phosphoric Acid Etch for 15-30 seconds followed by 10 second light cured optibond solo. IRM (Zinc Oxide Eugenol) cement is then placed to seal the pulp chamber. A stainless steel crown cemented with Ketac Cement for the full coverage final restoration completes the pulpotomy procedure.
Following the pulpotomy procedures, the teeth will be evaluated for clinical and radiographic success at 6 months post-op and 12 months post-op appointments at the Tapper Pediatric Dental Clinic at Rainbow Babies Children's Hospital. The study teeth treated will be evaluated clinically based on the presence of the following: (1) pain (2) abscess (3) mobility. Radiographic success will be determined by evaluating a bite wing x-ray taken at the two post-op appointments for the presence of the following: (1) internal resorption (2) external resorption and (3) furcation radiolucency.
Risks:
The only physical risk in laser therapy is the risk of eye damage. While eye damage has not been reported to date, we must still consider it as a possible risk. Because these study subjects will be under General Anesthesia their eyes will already be closed and covered. Suitable protective goggles should be worn by the investigator and assistants. Other possible risks associated with this study include risks from anesthesia- (Nausea, vomiting, epistaxis, fever, discomfort/pain). There are minimal to no risks involved in this research study.
Benefits:
Pulpotomy treatment maintains the vitality of the tooth as well as the supporting tissues. The longevity and prognosis of having a laser pulpotomy versus a formocresol pulpotomy treatment has been considered to be just as beneficial. Through this research study, we can further prove this new finding. Maintaining your primary dentition is extremely important and this study will provide insight on how advances in dental technology can help better treat carious teeth in more efficient and painless ways.
Alternatives:
Due to the nature of this research the only alternative is to not participate in this study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Formocresol (control) | Placebo comparator | Procedure: Formocresol application after pulpotomy preparationThis will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. IRM (Zinc Oxide Eugenol) cement will then be placed to seal the pulp chamber. A stainless steel crown will be cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration. |
| Laser | Active comparator | Procedure: GENTLEray 980 Soft Tissue diode laserThis will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Then a GENTLEray 980 Soft Tissue diode laser (Power: 3.0W, Mode: PW, Fiber: 300µm, Ton: 100ms, Toff: 100ms, Timer: cont) will be used to vaporize the residual pulp tissue and complete hemostasis. IRM (Zinc Oxide Eugenol) cement is then placed to seal the pulp chamber. A stainless steel crown cemented with Ketac Cement for the full coverage final restoration completes the pulpotomy procedure. |
Who may qualify
- Ages
- 3 to 8 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Restorable carious primary molars with reversible pulpitis and free of clinical or radiographic signs of pulp pathology
- Males and females
- Children ages 3-8 years old
- Children classified under ASA I or II status
Key exclusion criteria (5 listed)
- Excluded will be primary molars with clinical or radiographic signs of pathology
- Children not within age range
- Absence of parent/caregiver
- Mentally disabled parent/caregiver
- Patients not returning for 6 month and 12 month follow up examination appointment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Formocresol application after pulpotomy preparationAlso: Buckley's solution, baby root canal, primary root canal1:5 Buckley's Formocresol dilution applied for 5 minutes or until hemostasis achieved | Procedure or surgery | Formocresol (control) |
| GENTLEray 980 Soft Tissue diode laserAlso: soft tissue laser, electrosurgery, baby root canalApplication to pulp chamber until hemostasis achieved | Procedure or surgery | Laser |
Primary outcome
Radiographic
Time frame: 6, 12, and 18 months
Failure is identified as radiographic: furcation radiolucency, external root resorption
1 secondary outcome
Clinical
Time frame: 6, 12, 18 months
Results and safety
The study was stopped early (reason given: Use of Formocresol for pulpotomies ws discontinued.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 May 2017.
Related trials for Reversible Pulpitis
Not yet recruiting
Effect of Hemostatic Agents on TheraCal PT Pulpotomy Success in Primary Molars
Reversible Pulpitis, Dental Caries
Recruiting
Pomegranate Peel Extract for Primary Molar Pulpotomy
Pulpitis Reversible, Pulp Exposure, Dental
Recruiting
Pelargonium Graveolens Essential Oil as a Pulpotomy Agent in Primary Teeth
Pulpitis - Reversible, Pulpotomies on Primary Molars
Active, not recruiting
Pulp Inflammatory Markers and Outcome of Pulpotomy
Pulpitis in Permanent Teeth, Dental Caries Extending to Pulp
Recruiting
Comparative Evaluation of Direct Pulp Capping Between Deep and Extremely Deep Caries in Mature Permanent Mandibular Molars .
Reversible Pulpitis, Deep Caries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gerald A Ferretti, DDS, MS, MPH principal investigator
University Hospitals Cleveland Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Formocresol application after pulpotomy preparation and GENTLEray 980 Soft Tissue diode laser in people with Reversible Pulpitis and Caries, run by University Hospitals Cleveland Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 10 May 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Use of Formocresol for pulpotomies ws discontinued.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Radiographic (time frame: 6, 12, and 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 May 2017.